SCHEMBL10084346

SCHEMBL10084346

CCOC(=O)/C(O)=C/c1ccccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
LMNA P02545 5/20 0.49
MAPT P10636 4/20 0.49
PLIN1 O60240 1/20 0.49
POLB P06746 1/20 0.49
PLIN5 Q00G26 1/20 0.49
ABHD5 Q8WTS1 1/20 0.49
CASP1 P29466 1/20 0.47
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
GAA P10253 4/20 0.42
TDP1 Q9NUW8 1/20 0.42
HPGD P15428 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
TP53 P04637 1/20 0.41
GPR35 Q9HC97 1/20 0.41
NR1H4 Q96RI1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11781170 0.86 MAPT (0.66) MEN1KMT2ALMNAMAPTPLIN1
SCHEMBL6219624 0.84 LMNA (0.49) MEN1KMT2ALMNAMAPTPLIN1
SCHEMBL6219620 0.84 LMNA (0.49) MEN1KMT2ALMNAMAPTPLIN1
SCHEMBL4778791 0.82 MEN1 (0.57) MEN1KMT2ALMNAMAPTPLIN1
SCHEMBL4778793 0.82 MEN1 (0.57) MEN1KMT2ALMNAMAPTPLIN1
SCHEMBL22993782 0.81 ALDH1A1 (0.60) MEN1KMT2ALMNAMAPTPLIN1
SCHEMBL15395718 0.81 MEN1 (0.53) MEN1KMT2ALMNAMAPTPLIN1
SCHEMBL1676566 0.81 MEN1 (0.53) MEN1KMT2ALMNAMAPTPLIN1
SCHEMBL12469568 0.80 MAPT (0.59) MEN1KMT2ALMNAMAPTPLIN1
SCHEMBL12469566 0.80 MAPT (0.59) MEN1KMT2ALMNAMAPTPLIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174065-B2 Antidiabetic enolic glucoside of phenylpyruvic acid ZADEC APS (DK) 2019-01-08 US disclosed
US-20160083411-A1 ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID ZADEC APS (DK) 2016-03-24 US disclosed
US-20160083411-A1 ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID ZADEC APS (DK) 2016-03-24 US disclosed
US-9221860-B2 Antidiabetic enolic glucoside of phenylpyruvic acid ZADEC APS (DK) 2015-12-29 US disclosed
US-9221860-B2 Antidiabetic enolic glucoside of phenylpyruvic acid ZADEC APS (DK) 2015-12-29 US disclosed
EP-2625184-B1 ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID ZADEC APS (DK) 2014-10-01 EP disclosed
US-20130310331-A1 ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID ZADEC APS (DK) 2013-11-21 US disclosed
WO-2012045363-A1 ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID ZADEC APS (DK) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174065-B2 Antidiabetic enolic glucoside of phenylpyruvic acid PC, SLC5A1, SLC5A2 MEN1 3508/4885KMT2A 4011/4885LMNA 1605/4885
US-20160083411-A1 ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID PC, SLC5A1, SLC5A2 MEN1 3508/4885KMT2A 4011/4885LMNA 1605/4885
US-20130310331-A1 ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID PC, SLC5A1, SLC5A2 MEN1 3508/4885KMT2A 4011/4885LMNA 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.